- Report
- August 2026
- 328 Pages
Global
From €2621EUR$2,800USD£2,191GBP
€3276EUR$3,500USD£2,738GBP
- Report
- May 2026
- 130 Pages
Global
From €4539EUR$4,850USD£3,794GBP
- Report
- September 2026
Europe
From €4492EUR$4,799USD£3,754GBP
- Report
- August 2026
- 120 Pages
United States
From €3697EUR$3,950USD£3,090GBP
- Report
- May 2026
- 102 Pages
Middle East
From €3697EUR$3,950USD£3,090GBP
- Report
- May 2026
- 85 Pages
Africa
From €2667EUR$2,850USD£2,230GBP
- Report
- June 2023
- 289 Pages
Global
From €4891EUR$5,409USD£3,950GBP
- Report
- November 2026
Global
From €450EUR$515USD£389GBP
- Report
- November 2026
Global
From €300EUR$343USD£260GBP
- Report
- August 2023
- 270 Pages
Global
From €2293EUR$2,450USD£1,917GBP
- Report
- September 2025
- 313 Pages
Global
From €4633EUR$4,950USD£3,873GBP
- Report
- January 2025
- 456 Pages
Global
From €4633EUR$4,950USD£3,873GBP
- Report
- December 2024
- 581 Pages
Global
From €4633EUR$4,950USD£3,873GBP
- Report
- June 2023
- 186 Pages
Global
From €4352EUR$4,650USD£3,638GBP
- Report
- January 2025
- 180 Pages
Global
From €5569EUR$5,950USD£4,655GBP
- Report
- September 2023
- 168 Pages
Global
From €5569EUR$5,950USD£4,655GBP
- Report
- September 2023
- 190 Pages
Global
From €2331EUR$2,490USD£1,948GBP
- Report
- March 2022
- 182 Pages
Global
From €2457EUR$2,625USD£2,054GBP
€4914EUR$5,250USD£4,107GBP
- Report
- October 2025
- 120 Pages
Global
From €5569EUR$5,950USD£4,655GBP
- Report
- April 2025
Global
From €4586EUR$4,900USD£3,833GBP

Prostate cancer is a type of cancer that affects the prostate, a small walnut-shaped gland in men that produces the seminal fluid that nourishes and transports sperm. It is the most common cancer in men in the United States, and the second most common cause of cancer death in men. Prostate cancer is typically treated with surgery, radiation therapy, hormone therapy, chemotherapy, or a combination of these treatments.
The prostate cancer market within the oncology space is a rapidly growing segment, driven by the increasing prevalence of the disease and the development of new treatments. The market is expected to benefit from the introduction of novel therapies, such as immunotherapies and targeted therapies, which are expected to improve the prognosis of patients. Additionally, the increasing focus on early diagnosis and the development of new diagnostic tools are expected to drive the market growth.
Some of the key players in the prostate cancer market include AstraZeneca, Bayer AG, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Sanofi. Show Less Read more